---
title: "Varegacestat (AL102) in Desmoid tumors: Gamma secretase inhibitors"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Gamma secretase inhibitors. Topics: Nirogacestat: FDA-approved indication and mechanism, Nirogacestat: recommended dosage and dose modifications, Nirogacestat warnings: diarrhea, Nirogacestat warnings: ovarian toxicity, and 16 further topics. 20 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/gamma-secretase-inhibitors"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Gamma secretase inhibitors

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Gamma Secretase Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

### Nirogacestat: FDA-approved indication and mechanism

> “Initial U.S. Approval: 2023”
> “OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.”
> “Nirogacestat is a gamma secretase inhibitor that blocks proteolytic activation of the Notch receptor. When dysregulated, Notch can activate pathways that contribute to tumor growth.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Nirogacestat: recommended dosage and dose modifications

> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity.”
> “Instruct patients to swallow OGSIVEO tablets whole and not to break, crush, or chew prior to swallowing.”
> “For other severe adverse reactions, life-threatening adverse reactions, or persistent intolerable Grade 2 adverse reactions, withhold drug until resolved to Grade ≤ 1 or baseline. Only restart at a dosage of 100 mg twice daily after considering the potential benefit and likelihood of recurrence of the adverse reaction.”
> “Permanently discontinue OGSIVEO for recurrence of severe or life-threatening adverse reaction upon rechallenge at the reduced dose.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Nirogacestat warnings: diarrhea

> “Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO”
> “Median time to first diarrhea event for patients treated with OGSIVEO was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### Nirogacestat warnings: ovarian toxicity

> “Female reproductive function and fertility may be impaired in patients being treated with OGSIVEO. Impact on fertility may depend on factors including the duration of therapy and the state of gonadal function at the time of treatment. The long-term effects of OGSIVEO on fertility have not been established.”
> “Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.”
> “OGSIVEO can affect ovarian function and the development of the ovarian follicle and therefore may reduce the effectiveness of hormonal contraceptives. Addition of a barrier method is recommended for females using hormonal contraceptives.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

### Nirogacestat warnings: hepatotoxicity

> “ALT or AST elevations occurred in 30% and 33% of patients who received OGSIVEO in DeFi, respectively. Grade 3 ALT or AST elevations (> 5 × ULN) occurred in 6% and 2.9% of patients, respectively”
> “Monitor liver function tests regularly and modify dose as recommended”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

### Nirogacestat warnings: non-melanoma skin cancers

> “New non-melanoma skin cancers can occur in patients treated with OGSIVEO. In DeFi, cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively”
> “Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

### Nirogacestat warnings: electrolyte abnormalities

> “Electrolyte abnormalities can occur in patients treated with OGSIVEO. In DeFi, these included decreased phosphate (65%) and decreased potassium (22%). Phosphate <2 mg/dL occurred in 20% of patients who received OGSIVEO. Grade 3 decreased potassium occurred in 1.4% of patients”
> “Monitor phosphate and potassium levels regularly and supplement as necessary.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

### Nirogacestat warnings: hypersensitivity reactions, added August 2026

> “Warnings and Precautions (5.6)”
> “08/2026”
> “Hypersensitivity reactions, including severe hypersensitivity reactions, have been reported with postmarketing use of OGSIVEO.”
> “Interrupt dosing or permanently discontinue OGSIVEO depending on the severity”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

### Nirogacestat warnings: embryo-fetal toxicity

> “Based on findings from animal studies and its mechanism of action, OGSIVEO can cause fetal harm when administered to pregnant women.”
> “Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

### Nirogacestat: drug interactions

> “Strong or moderate CYP3A inhibitors: Avoid concomitant use. (7.1)”
> “Strong or moderate CYP3A inducers: Avoid concomitant use. (7.1)”
> “Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors and H2-receptor antagonists.”
> “Nirogacestat Cmax increased 2.5-fold and AUC 8.2-fold following coadministration of a single dose of OGSIVEO (100 mg) with itraconazole (a strong CYP3A inhibitor).”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-11"></a>

### DeFi phase 3 trial: design

> “We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival.”
> “From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.1.5-12"></a>

### DeFi phase 3 trial: efficacy

> “The risk of disease progression or death was 71% lower in the nirogacestat group than in the placebo group (hazard ratio, 0.29; 95% confidence interval [CI], 0.15 to 0.55; P<0.001)”
> “The likelihood of being event-free at 1 year was 85% (95% CI, 73 to 92) with nirogacestat and 53% (95% CI, 40 to 64) with placebo. The likelihood of being event-free at 2 years was 76% (95% CI, 61 to 87) with nirogacestat and 44% (95% CI, 32 to 56) with placebo.”
> “The percentage of patients with a confirmed objective response was 41% in the nirogacestat group and 8% in the placebo group (P<0.001). Complete responses were observed in 7% of the patients in the nirogacestat group and no patients in the placebo group”
> “Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life, were observed (P≤0.01).”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.1.5-13"></a>

### DeFi phase 3 trial: safety

> “Dose reductions due to adverse events were more frequently reported among patients receiving nirogacestat (42%) than among those receiving placebo (0%) and were attributed primarily to diarrhea, stomatitis, maculopapular rash, hypophosphatemia, hidradenitis, ovarian failure, and folliculitis. Adverse events led to discontinuation of the trial regimen in 14 patients (20%) in the nirogacestat group and 1 patient (1%) in the placebo group.”
> “Ovarian dysfunction (defined by the MedDRA preferred terms of amenorrhea, premature menopause, menopause, and ovarian failure) occurred in 27 of 36 women of childbearing potential (75%) receiving nirogacestat and in 0 of 37 receiving placebo. The median time to first onset of ovarian dysfunction was 8.9 weeks, and the median duration across ovarian dysfunction events was 19.1 weeks.”
> “Although long-term treatment with nirogacestat was shown to be feasible (median treatment duration, 20.6 months), the appropriate treatment duration is unknown.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.1.5-14"></a>

### DeFi long-term follow-up through December 2024

> “Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024.”
> “The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis.”
> “Of the 70 patients randomly assigned to nirogacestat in the DB phase, 39 continued in the OLE”
> “Overall, 33 and 15 patients received nirogacestat for at least 3 and 4 years, respectively.”
> “No additional events (progression or death) occurred with additional exposure after year 2”
> “The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.”
> “Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4.”
> “Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

<a id="topic-2.2.2.1.5-15"></a>

### DeFi ovarian toxicity: onset and resolution in females of reproductive potential

> “This analysis further describes the incidence, presentation, and resolution of OT.”
> “OT was identified in 75% (27 of 36) receiving nirogacestat and 0% (0 of 37) receiving placebo. As of October 24, 2022, investigators reported OT resolution in 78% (21 of 27) of patients, with median OT duration of 19.1 weeks.”
> “Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment”
> “Resolution was reported in 10 of 14 (71%) while on nirogacestat”
> “Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.”

Source: [Loggers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38703010/)

<a id="topic-2.2.2.1.5-16"></a>

### Duration of nirogacestat treatment: DeFi investigators' reply on long-term use

> “We do not endorse long-term uninterrupted treatment with nirogacestat as the standard of care. Still, as both groups of authors have acknowledged, the optimal treatment duration remains undefined.”
> “However, patients in DeFi were censored at the time nirogacestat was discontinued and were followed for no more than 30 days after treatment discontinuation. Therefore, the absence of progression events after year 2 reflects only the cohort of patients who continued treatment.”

Source: [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/)

<a id="topic-2.2.2.1.5-17"></a>

### Real-world nirogacestat use in the French compassionate use program (DeNi study)

> “The DeNi study reports outcomes of patients treated with nirogacestat through the French compassionate use program. DeNi is a retrospective, real-world study.”
> “Between February and June 2024, 55 patients with desmoid tumors were included (37 women).”
> “Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions.”
> “Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.”
> “The most frequent side effects (all grades) were diarrhea (53%), fatigue (47%), and rash (29%). Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.”

Source: [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)

<a id="topic-2.2.2.1.5-18"></a>

### NCCN guideline status as restated in a payer policy and in a DeFi publication

> “The National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 1.2025 – May 2, 2025) recommend the following therapies as”
> “regimens for desmoid tumors (aggressive fibromatosis):”
> “Ogsiveo (category 1), sorafenib (category 1), methotrexate and vinorelbine, methotrexate and vinblastine, imatinib, pazopanib, doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection) [except for Ogsiveo and sorafenib, all other agents listed are category 2A recommendations].”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

> “Nirogacestat, an oral, targeted gamma secretase inhibitor, is the only US Food and Drug Administration–and European Commission–approved therapy for adults with progressing DT who require systemic treatment and is recommended as a preferred therapy by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

<a id="topic-2.2.2.1.5-19"></a>

### European marketing authorisation of nirogacestat

> “Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.”
> “Marketing authorisation issued”
> “14/08/2025”

Source: [EMA Ogsiveo EPAR (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/ogsiveo)

> “Approval from the European Commission was obtained in August 2025 and from the UK Medicines and Healthcare Products Regulatory Agency in January 2026.”
> “However, as of this writing, nirogacestat is still not widely available outside of the United States.”

Source: [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/)

<a id="topic-2.2.2.1.5-20"></a>

### NICE technology appraisal TA1199 recommendation, October 2026

> “14 October 2026”
> “Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if the company provides it according to the commercial arrangement.”
> “Usual treatment for progressing desmoid tumours that need systemic treatment is non-curative and aims to manage symptoms. This can include chemotherapy, which is not licensed for treating desmoid tumours.”
> “Nirogacestat has not been directly compared with chemotherapy in a clinical trial. Indirect comparisons suggest that nirogacestat is likely to work as well as chemotherapy, but this is uncertain.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

Additional sources: [Dossa et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42030529/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
